TMS Co., Ltd. (4891.T)
JPY 149.0
(-1.97%)
JPY 149.0
(-1.97%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.55 Billion JPY | -6.21% |
| 2022 | 3.79 Billion JPY | 38.34% |
| 2021 | 2.73 Billion JPY | 125.82% |
| 2020 | 1.21 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.32 Billion JPY | -6.43% |
| 2024 Q2 | 3.08 Billion JPY | -7.18% |
| 2023 Q3 | 3.22 Billion JPY | -6.04% |
| 2023 FY | 3.55 Billion JPY | -6.21% |
| 2023 Q2 | 3.43 Billion JPY | -5.45% |
| 2023 Q1 | 3.63 Billion JPY | -4.07% |
| 2023 Q4 | 3.55 Billion JPY | 10.06% |
| 2022 Q2 | 2.07 Billion JPY | 0.0% |
| 2022 Q4 | 3.79 Billion JPY | -5.2% |
| 2022 Q3 | 3.99 Billion JPY | 92.49% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 46.053% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -193.436% |
| GNI Group Ltd. | 62.39 Billion JPY | 94.303% |
| Linical Co., Ltd. | 18.53 Billion JPY | 80.826% |
| Trans Genic Inc. | 9.81 Billion JPY | 63.768% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 36.907% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 48.824% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 38.883% |
| AnGes, Inc. | 28.89 Billion JPY | 87.697% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -309.876% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 97.739% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -119.621% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 29.904% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 18.279% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -46.115% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -49.777% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 48.707% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -102.96% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 30.101% |
| PeptiDream Inc. | 67.12 Billion JPY | 94.704% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -74.202% |
| Ribomic Inc. | 3.54 Billion JPY | -0.211% |
| SanBio Company Limited | 5.04 Billion JPY | 29.571% |
| Healios K.K. | 15.15 Billion JPY | 76.544% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -188.944% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -17.863% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -141.138% |
| StemRIM | 9.08 Billion JPY | 60.851% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 48.33% |
| FunPep Company Limited | 2.49 Billion JPY | -42.696% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -35.747% |
| Stella Pharma Corporation | 3.82 Billion JPY | 6.959% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 38.488% |
| Cuorips Inc. | 6.18 Billion JPY | 42.524% |
| K Pharma,Inc. | 3.31 Billion JPY | -7.268% |
| Takara Bio Inc. | 123.2 Billion JPY | 97.115% |
| ReproCELL Incorporated | 9.05 Billion JPY | 60.732% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -30.915% |
| StemCell Institute Inc. | 6.54 Billion JPY | 45.672% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 49.136% |
| CellSeed Inc. | 2.46 Billion JPY | -44.164% |